[go: up one dir, main page]

DK1604679T3 - Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte - Google Patents

Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte

Info

Publication number
DK1604679T3
DK1604679T3 DK05006623.2T DK05006623T DK1604679T3 DK 1604679 T3 DK1604679 T3 DK 1604679T3 DK 05006623 T DK05006623 T DK 05006623T DK 1604679 T3 DK1604679 T3 DK 1604679T3
Authority
DK
Denmark
Prior art keywords
treatment
botulinum toxin
visceral pain
visceral
pain
Prior art date
Application number
DK05006623.2T
Other languages
English (en)
Inventor
Kei Roger Aoki
Minglei Cui
Stephen Jenkins
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24196890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1604679(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1604679T3 publication Critical patent/DK1604679T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK05006623.2T 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte DK1604679T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/550,371 US6464986B1 (en) 2000-04-14 2000-04-14 Method for treating pain by peripheral administration of a neurotoxin
EP01924939A EP1272207B1 (en) 2000-04-14 2001-04-11 Use of a botulinum toxin for the manufacture of a medicament for peripheral administration for treating pain non associated to muscle spasm or headache

Publications (1)

Publication Number Publication Date
DK1604679T3 true DK1604679T3 (da) 2010-10-25

Family

ID=24196890

Family Applications (6)

Application Number Title Priority Date Filing Date
DK05006623.2T DK1604679T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte
DK05006625.7T DK1604681T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoksin til behandling af ledsmerte
DK05006624.0T DK1604680T3 (da) 2000-04-14 2001-04-11 Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte
DK05006627.3T DK1576963T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoxin til behandling af en af infektion forårsaget smerte
DK01924939T DK1272207T3 (da) 2000-04-14 2001-04-11 Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine
DK05006622.4T DK1604678T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af postoperativ smerte

Family Applications After (5)

Application Number Title Priority Date Filing Date
DK05006625.7T DK1604681T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoksin til behandling af ledsmerte
DK05006624.0T DK1604680T3 (da) 2000-04-14 2001-04-11 Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte
DK05006627.3T DK1576963T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoxin til behandling af en af infektion forårsaget smerte
DK01924939T DK1272207T3 (da) 2000-04-14 2001-04-11 Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine
DK05006622.4T DK1604678T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af postoperativ smerte

Country Status (19)

Country Link
US (14) US6464986B1 (da)
EP (7) EP1550456B1 (da)
JP (1) JP4037652B2 (da)
KR (1) KR20030009431A (da)
CN (1) CN1188165C (da)
AR (1) AR030209A1 (da)
AT (6) ATE480253T1 (da)
AU (2) AU5154601A (da)
BR (1) BR0110030A (da)
CA (3) CA2485919A1 (da)
CY (2) CY1108065T1 (da)
DE (6) DE60143061D1 (da)
DK (6) DK1604679T3 (da)
ES (7) ES2353878T3 (da)
MX (1) MXPA02009932A (da)
NZ (1) NZ521535A (da)
PT (2) PT1604680E (da)
TW (1) TWI282282B (da)
WO (1) WO2001078760A2 (da)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US6977080B1 (en) 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
JP2004521067A (ja) * 2000-06-28 2004-07-15 サンダース，イラ 動物（哺乳動物）における有用な用途を目的とする破傷風毒素の使用方法
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
ITUD20010002A1 (it) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US20030022926A1 (en) * 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US20030100574A1 (en) 2001-11-15 2003-05-29 Wilson Nestor Antonio Lagos Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
CA2493041C (en) * 2002-07-19 2011-08-16 Dominik Meyer Injectable pharmaceutical composition for treating post-operative joint pain comprising an amide local anesthetic
AU2003287155A1 (en) * 2002-10-15 2004-05-04 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US20060153876A1 (en) * 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
BRPI0408114A (pt) * 2003-03-06 2006-03-01 Botulinum Toxin Res Ass Inc tratamento de calázio crÈnico e hordéolo com toxina botulinìca
US7670608B2 (en) * 2003-03-06 2010-03-02 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
AU2004216904B2 (en) * 2003-03-06 2009-12-24 Botulinum Toxin Research Associates, Inc. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) * 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
CA2607206C (en) * 2004-05-07 2016-06-14 Phytotox Limited Transdermal administration of phycotoxins
US20080021051A1 (en) * 2004-05-07 2008-01-24 Phytotox Limited Phycotoxins and Uses Thereof
KR100668570B1 (ko) 2004-06-28 2007-01-16 입센 리미티드 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
GB2417419A (en) * 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
WO2006026780A1 (en) 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
EP2298339B1 (en) 2004-09-23 2015-07-15 Toxcure, Inc. Treating neoplasms with neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
CN1930186A (zh) 2005-03-03 2007-03-14 阿勒根公司 为获得梭菌毒素的梭菌细菌培养基及方法
CA2601592A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
ES2351942T3 (es) 2005-04-05 2011-02-14 Allergan Inc Analisis de la actividad de una toxina clostridial.
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
EP2248534A1 (en) * 2005-06-14 2010-11-10 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
CN103315954A (zh) * 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
TR201901443T4 (tr) 2005-12-01 2019-02-21 Univ Massachusetts Lowell Botulinum nanoemülsiyonları.
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
CA2671133C (en) 2006-12-01 2015-11-24 Anterios, Inc. Peptide nanoparticles and uses therefor
EP2494958A1 (en) 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
CA2678038C (en) 2007-02-15 2016-10-11 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
DE102007038015A1 (de) * 2007-08-10 2009-02-19 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Verwendung eines Neurotoxins
JP2009132672A (ja) * 2007-10-31 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチドを有効成分として含む鎮痛作用を有する医薬組成物
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
KR20160130519A (ko) * 2008-06-26 2016-11-11 안테리오스, 인코퍼레이티드 경피 운반
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
WO2010016895A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
US20100034854A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 KD)
WO2010051039A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
WO2010051038A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
AU2010221435B2 (en) 2009-03-06 2014-06-19 Allergan, Inc. Clostridial toxin to improve ejaculate
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
US8975233B2 (en) * 2010-01-26 2015-03-10 Northwind Medical, Inc. Methods for renal denervation
JP2011157331A (ja) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst 高用量投与が可能なボツリヌス毒素製剤
WO2012103415A1 (en) 2011-01-28 2012-08-02 Allergan, Inc. Dosage regimen for the treatment of multiple disorders with botulinum toxins
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
CN103747796A (zh) 2011-07-08 2014-04-23 阿勒根公司 用于治疗自主神经系统病症的方法
AU2012280947B2 (en) 2011-07-14 2016-04-07 Allergan, Inc. Methods for treatment of incontinence associated with sexual activity
BR112014001066A2 (pt) 2011-07-20 2017-02-21 Allergan Inc toxinas botulínicas para uso em um método para tratamento de depósitos adiposos
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
AU2014234190A1 (en) 2013-03-22 2015-09-10 Lipotec S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US10537619B2 (en) * 2014-09-12 2020-01-21 Allergan, Inc. Methods for treating osteoarthritis pain
DK3242884T3 (da) 2015-01-09 2021-04-19 Ipsen Bioinnovation Ltd Kationiske neurotoksiner
EP3355938B1 (en) 2015-10-01 2024-02-07 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
JP7118055B2 (ja) 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
KR20190142404A (ko) 2017-05-24 2019-12-26 주식회사 에이티지씨 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US20210187194A1 (en) 2018-02-26 2021-06-24 Ipsen Biopharm Limited Use of Ultrasound to Guide Injection of Non-cytotoxic Protease
WO2019224184A1 (en) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
EP3660509B1 (en) 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
KR20250069883A (ko) 2022-09-30 2025-05-20 입센 바이오팜 리미티드 방광 통증 증후군 치료에 사용되는 클로스트리디움 신경독소
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693207B1 (fr) * 1992-07-03 1994-09-30 Orsan Souche de levure permettant la co-expression d'une activité mono-oxygénase de cytochrome P450 hétérologue et d'une NADPH-cytochrome P450-réductase endogène ou hétérologue et son utilisation à des fins de bioconversion.
AU6030494A (en) 1993-01-15 1994-08-15 Associated Synapse Biologics Method for treating myofascial pain syndrome
US5592212A (en) * 1993-04-16 1997-01-07 News Datacom Ltd. Methods and systems for non-program applications for subscriber television
EP1602379A1 (en) * 1993-12-28 2005-12-07 Allergan, Inc. Botulinum toxin B for treating spastic muscle
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DE69526340T2 (de) 1994-05-09 2002-11-14 William J. Binder Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
JPH08306853A (ja) * 1995-05-09 1996-11-22 Fujitsu Ltd 半導体装置及びその製造方法及びリードフレームの製造方法
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
WO2006017004A1 (en) 2004-07-07 2006-02-16 Obstecare Inc. Method for monitoring a childbirth process

Also Published As

Publication number Publication date
US6464986B1 (en) 2002-10-15
ATE456375T1 (de) 2010-02-15
US20050152925A1 (en) 2005-07-14
EP1576963A2 (en) 2005-09-21
US20080138364A1 (en) 2008-06-12
EP1550456A2 (en) 2005-07-06
US7211262B2 (en) 2007-05-01
DE60142590D1 (de) 2010-08-26
ES2287117T3 (es) 2007-12-16
TWI282282B (en) 2007-06-11
AR030209A1 (es) 2003-08-13
EP1604680A1 (en) 2005-12-14
DE60128899D1 (de) 2007-07-26
US20060275326A1 (en) 2006-12-07
DE60143061D1 (de) 2010-10-21
EP1604679B1 (en) 2010-07-28
US20070014816A1 (en) 2007-01-18
US7468189B2 (en) 2008-12-23
ATE364393T1 (de) 2007-07-15
US6869610B2 (en) 2005-03-22
CA2406367A1 (en) 2001-10-25
US20050058666A1 (en) 2005-03-17
US20060039917A1 (en) 2006-02-23
CA2485920A1 (en) 2001-10-25
JP4037652B2 (ja) 2008-01-23
US7361358B2 (en) 2008-04-22
EP1550456A3 (en) 2005-12-07
US20060275325A1 (en) 2006-12-07
DK1272207T3 (da) 2007-09-10
DE60128899T2 (de) 2008-02-21
CA2485919A1 (en) 2001-10-25
JP2003531127A (ja) 2003-10-21
WO2001078760A2 (en) 2001-10-25
EP1604679A1 (en) 2005-12-14
AU2001251546B2 (en) 2004-07-01
ES2349782T3 (es) 2011-01-11
EP1576963A3 (en) 2005-12-07
EP1272207B1 (en) 2007-06-13
AU2001251546B9 (en) 2004-12-02
DE60143549D1 (de) 2011-01-05
US7291344B2 (en) 2007-11-06
ES2338238T3 (es) 2010-05-05
ES2353878T3 (es) 2011-03-07
EP1604681A1 (en) 2005-12-14
US20040018212A1 (en) 2004-01-29
PT1604680E (pt) 2010-02-11
ATE473753T1 (de) 2010-07-15
DE60141230D1 (de) 2010-03-18
BR0110030A (pt) 2003-06-03
ES2394314T3 (es) 2013-01-30
US7067137B2 (en) 2006-06-27
US20020176872A1 (en) 2002-11-28
CA2406367C (en) 2008-01-29
US20040018213A1 (en) 2004-01-29
US7172763B2 (en) 2007-02-06
CN1188165C (zh) 2005-02-09
ATE480253T1 (de) 2010-09-15
MXPA02009932A (es) 2004-08-19
ATE489102T1 (de) 2010-12-15
US20060039916A1 (en) 2006-02-23
EP1604681B1 (en) 2010-09-08
DK1576963T3 (da) 2011-02-21
CN1436085A (zh) 2003-08-13
US20040028706A1 (en) 2004-02-12
AU5154601A (en) 2001-10-30
CY1109972T1 (el) 2014-09-10
DE60142712D1 (de) 2010-09-09
EP1550456B1 (en) 2012-09-26
EP1604678B1 (en) 2010-07-14
WO2001078760A3 (en) 2002-03-21
EP1272207A2 (en) 2003-01-08
US7276245B2 (en) 2007-10-02
EP1604680B1 (en) 2010-01-27
DK1604680T3 (da) 2010-05-10
ES2347256T3 (es) 2010-10-27
ATE475427T1 (de) 2010-08-15
US7288260B2 (en) 2007-10-30
DK1604678T3 (da) 2010-10-18
US7374769B2 (en) 2008-05-20
DK1604681T3 (da) 2010-11-29
NZ521535A (en) 2004-09-24
US7294339B2 (en) 2007-11-13
US20040018214A1 (en) 2004-01-29
PT1272207E (pt) 2007-06-29
EP1576963B1 (en) 2010-11-24
ES2347792T3 (es) 2010-11-04
CY1108065T1 (el) 2014-02-12
KR20030009431A (ko) 2003-01-29
EP1604678A1 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
DK1604679T3 (da) Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte
DK1250146T3 (da) Anvendelse af botulinumtoxin til behandling af diabetes
ATE473944T1 (de) Mittel zur wasserbehandlung
DE60017241D1 (de) Unterwasserbehandlungsanordnung und -verfahren
EE05073B1 (et) Retigabiin kasutamiseks neuropaatilise valu ravis
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
DK1267650T3 (da) Tobakbehandling
DE60114033D1 (de) Entschwefelung und hierfür geeignetes sorbens
BR0205514B1 (pt) processos de tratamento de cabelo
NO20032122L (no) Forbedret behandling
DE60223576D1 (de) Hautbehandlungszusammensetzung
PT1248608E (pt) Substancias para usar no tratamento de psoriase
PT1326628E (pt) Mutantes de quimioquinas no tratamento de esclerose multipla
DE60102459D1 (de) Lockenwickler
DE60111520D1 (de) Hydroxyphenyl-piperazinyl-methyl-benzamid-derivate zur schmerzbehandlung
DE60023003D1 (de) Haarbehandlungsmittel
DE60125241D1 (de) Wärmebehandlungseinrichtung
BR0114005B1 (pt) composição para tratamento de tecido
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
FI4299U1 (fi) Saunasuodatin
FI20030276A7 (fi) Palovammojen hoitaminen
DE50109641D1 (de) Textilbehandlungsmittel
DE60131616D1 (de) Dressing oder Marinade
ATE285468T1 (de) Gewebehandlungszubereitung
EP1335496A4 (en) Encoder and decoder